Which has stronger earnings & valuation, CMPS or KMDA?

Kamada has higher revenue and earnings than Compass Pathways. Compass Pathways is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Compass Pathways N/A N/A -$287.86M -$3.15 N/A Kamada $180.46M 2.26 $20.20M $0.35 20.26

Is CMPS or KMDA more profitable?

Kamada has a net margin of 11.21% compared to Compass Pathways' net margin of 0.00%. Kamada's return on equity of 7.73% beat Compass Pathways' return on equity. Company Net Margins Return on Equity Return on Assets Compass Pathways N/A -31.07% -11.40% Kamada 11.21% 7.73% 5.41%

Does the media favor CMPS or KMDA?

In the previous week, Compass Pathways had 4 more articles in the media than Kamada. MarketBeat recorded 8 mentions for Compass Pathways and 4 mentions for Kamada. Compass Pathways' average media sentiment score of 1.06 beat Kamada's score of 0.45 indicating that Compass Pathways is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Pathways 5 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kamada 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, KMDA or SEPN?

Kamada has higher revenue and earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kamada $180.46M 2.26 $20.20M $0.35 20.26 Septerna $45.95M 31.60 -$48.88M -$0.81 N/A

Is KMDA or SEPN more profitable?

Kamada has a net margin of 11.21% compared to Septerna's net margin of -49.88%. Kamada's return on equity of 7.73% beat Septerna's return on equity. Company Net Margins Return on Equity Return on Assets Kamada 11.21% 7.73% 5.41% Septerna -49.88% -12.72% -8.87%

Does the media refer more to KMDA or SEPN?

In the previous week, Kamada had 2 more articles in the media than Septerna. MarketBeat recorded 4 mentions for Kamada and 2 mentions for Septerna. Kamada's average media sentiment score of 0.45 beat Septerna's score of 0.37 indicating that Kamada is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kamada 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Septerna 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, IMCR or KMDA?

Kamada has lower revenue, but higher earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunocore $400.02M 4.33 -$35.51M -$0.55 N/A Kamada $180.46M 2.26 $20.20M $0.35 20.26

Is IMCR or KMDA more profitable?

Kamada has a net margin of 11.21% compared to Immunocore's net margin of -6.68%. Kamada's return on equity of 7.73% beat Immunocore's return on equity. Company Net Margins Return on Equity Return on Assets Immunocore -6.68% -7.07% -2.55% Kamada 11.21% 7.73% 5.41%

Does the media favor IMCR or KMDA?

In the previous week, Kamada had 2 more articles in the media than Immunocore. MarketBeat recorded 4 mentions for Kamada and 2 mentions for Immunocore. Kamada's average media sentiment score of 0.45 beat Immunocore's score of 0.00 indicating that Kamada is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunocore 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kamada 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AVBP or KMDA?

In the previous week, Kamada had 2 more articles in the media than ArriVent BioPharma. MarketBeat recorded 4 mentions for Kamada and 2 mentions for ArriVent BioPharma. Kamada's average media sentiment score of 0.45 beat ArriVent BioPharma's score of 0.00 indicating that Kamada is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kamada 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor KMDA or MPLT?

In the previous week, Kamada had 3 more articles in the media than Maplight Therapeutics. MarketBeat recorded 4 mentions for Kamada and 1 mentions for Maplight Therapeutics. Kamada's average media sentiment score of 0.45 beat Maplight Therapeutics' score of 0.34 indicating that Kamada is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kamada 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Maplight Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Kamada (KMDA) Competitors

$7.09 +0.04 (+0.57%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$7.09 0.00 (0.00%)

As of 07/20/2026 07:34 PM Eastern

Compare

KMDA vs. CMPS, SEPN, IMCR, AVBP, and MPLT

Should you buy Kamada stock or one of its competitors? MarketBeat compares Kamada with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kamada include Compass Pathways (CMPS), Septerna (SEPN), Immunocore (IMCR), ArriVent BioPharma (AVBP), and Maplight Therapeutics (MPLT). These companies are all part of the "pharmaceutical products" industry.

How does Kamada compare to Compass Pathways?

Compass Pathways (NASDAQ:CMPS) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

Compass Pathways has a beta of 2.47, suggesting that its stock price is 147% more volatile than the broader market. Comparatively, Kamada has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market.

Kamada has a net margin of 11.21% compared to Compass Pathways' net margin of 0.00%. Kamada's return on equity of 7.73% beat Compass Pathways' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Pathways	N/A	-31.07%	-11.40%
Kamada	11.21%	7.73%	5.41%

Kamada has higher revenue and earnings than Compass Pathways. Compass Pathways is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A
Kamada	$180.46M	2.26	$20.20M	$0.35	20.26

In the previous week, Compass Pathways had 4 more articles in the media than Kamada. MarketBeat recorded 8 mentions for Compass Pathways and 4 mentions for Kamada. Compass Pathways' average media sentiment score of 1.06 beat Kamada's score of 0.45 indicating that Compass Pathways is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Pathways	5 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kamada	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Compass Pathways presently has a consensus price target of $24.15, indicating a potential upside of 106.97%. Kamada has a consensus price target of $12.00, indicating a potential upside of 69.25%. Given Compass Pathways' higher possible upside, equities research analysts clearly believe Compass Pathways is more favorable than Kamada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Pathways	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

46.2% of Compass Pathways shares are held by institutional investors. Comparatively, 20.4% of Kamada shares are held by institutional investors. 2.8% of Compass Pathways shares are held by company insiders. Comparatively, 36.1% of Kamada shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Kamada beats Compass Pathways on 9 of the 16 factors compared between the two stocks.

How does Kamada compare to Septerna?

Kamada (NASDAQ:KMDA) and Septerna (NASDAQ:SEPN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

Kamada presently has a consensus target price of $12.00, suggesting a potential upside of 69.25%. Septerna has a consensus target price of $45.89, suggesting a potential upside of 42.47%. Given Kamada's stronger consensus rating and higher probable upside, equities analysts clearly believe Kamada is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Kamada has a net margin of 11.21% compared to Septerna's net margin of -49.88%. Kamada's return on equity of 7.73% beat Septerna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kamada	11.21%	7.73%	5.41%
Septerna	-49.88%	-12.72%	-8.87%

20.4% of Kamada shares are held by institutional investors. 36.1% of Kamada shares are held by company insiders. Comparatively, 5.8% of Septerna shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Kamada has higher revenue and earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kamada	$180.46M	2.26	$20.20M	$0.35	20.26
Septerna	$45.95M	31.60	-$48.88M	-$0.81	N/A

In the previous week, Kamada had 2 more articles in the media than Septerna. MarketBeat recorded 4 mentions for Kamada and 2 mentions for Septerna. Kamada's average media sentiment score of 0.45 beat Septerna's score of 0.37 indicating that Kamada is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kamada	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Septerna	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kamada has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market. Comparatively, Septerna has a beta of 2.29, suggesting that its stock price is 129% more volatile than the broader market.

Summary

Kamada beats Septerna on 13 of the 17 factors compared between the two stocks.

How does Kamada compare to Immunocore?

Immunocore (NASDAQ:IMCR) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

Kamada has lower revenue, but higher earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$400.02M	4.33	-$35.51M	-$0.55	N/A
Kamada	$180.46M	2.26	$20.20M	$0.35	20.26

In the previous week, Kamada had 2 more articles in the media than Immunocore. MarketBeat recorded 4 mentions for Kamada and 2 mentions for Immunocore. Kamada's average media sentiment score of 0.45 beat Immunocore's score of 0.00 indicating that Kamada is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunocore	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kamada	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immunocore presently has a consensus price target of $56.71, suggesting a potential upside of 66.56%. Kamada has a consensus price target of $12.00, suggesting a potential upside of 69.25%. Given Kamada's stronger consensus rating and higher probable upside, analysts plainly believe Kamada is more favorable than Immunocore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.40
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Immunocore has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market. Comparatively, Kamada has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market.

Kamada has a net margin of 11.21% compared to Immunocore's net margin of -6.68%. Kamada's return on equity of 7.73% beat Immunocore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-6.68%	-7.07%	-2.55%
Kamada	11.21%	7.73%	5.41%

84.5% of Immunocore shares are owned by institutional investors. Comparatively, 20.4% of Kamada shares are owned by institutional investors. 10.1% of Immunocore shares are owned by company insiders. Comparatively, 36.1% of Kamada shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Kamada beats Immunocore on 12 of the 16 factors compared between the two stocks.

How does Kamada compare to ArriVent BioPharma?

ArriVent BioPharma (NASDAQ:AVBP) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership.

ArriVent BioPharma presently has a consensus price target of $44.83, indicating a potential upside of 58.87%. Kamada has a consensus price target of $12.00, indicating a potential upside of 69.25%. Given Kamada's stronger consensus rating and higher probable upside, analysts plainly believe Kamada is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Kamada has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A
Kamada	$180.46M	2.26	$20.20M	$0.35	20.26

Kamada has a net margin of 11.21% compared to ArriVent BioPharma's net margin of 0.00%. Kamada's return on equity of 7.73% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-48.98%	-45.44%
Kamada	11.21%	7.73%	5.41%

9.5% of ArriVent BioPharma shares are owned by institutional investors. Comparatively, 20.4% of Kamada shares are owned by institutional investors. 8.6% of ArriVent BioPharma shares are owned by company insiders. Comparatively, 36.1% of Kamada shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

ArriVent BioPharma has a beta of 1.29, indicating that its share price is 29% more volatile than the broader market. Comparatively, Kamada has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market.

In the previous week, Kamada had 2 more articles in the media than ArriVent BioPharma. MarketBeat recorded 4 mentions for Kamada and 2 mentions for ArriVent BioPharma. Kamada's average media sentiment score of 0.45 beat ArriVent BioPharma's score of 0.00 indicating that Kamada is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ArriVent BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kamada	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Kamada beats ArriVent BioPharma on 13 of the 16 factors compared between the two stocks.

How does Kamada compare to Maplight Therapeutics?

Kamada (NASDAQ:KMDA) and Maplight Therapeutics (NASDAQ:MPLT) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

In the previous week, Kamada had 3 more articles in the media than Maplight Therapeutics. MarketBeat recorded 4 mentions for Kamada and 1 mentions for Maplight Therapeutics. Kamada's average media sentiment score of 0.45 beat Maplight Therapeutics' score of 0.34 indicating that Kamada is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kamada	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maplight Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kamada has higher revenue and earnings than Maplight Therapeutics. Maplight Therapeutics is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kamada	$180.46M	2.26	$20.20M	$0.35	20.26
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A

20.4% of Kamada shares are held by institutional investors. 36.1% of Kamada shares are held by company insiders. Comparatively, 3.8% of Maplight Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Kamada has a net margin of 11.21% compared to Maplight Therapeutics' net margin of 0.00%. Kamada's return on equity of 7.73% beat Maplight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kamada	11.21%	7.73%	5.41%
Maplight Therapeutics	N/A	N/A	N/A

Kamada presently has a consensus target price of $12.00, suggesting a potential upside of 69.25%. Maplight Therapeutics has a consensus target price of $39.73, suggesting a potential upside of 10.38%. Given Kamada's higher probable upside, research analysts clearly believe Kamada is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	5 Strong Buy rating(s)	3.12

Summary

Kamada beats Maplight Therapeutics on 12 of the 15 factors compared between the two stocks.

Get Kamada News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KMDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KMDA vs. The Competition

Export

Metric	Kamada	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$405.41M	$3.69B	$6.89B	$12.28B
Dividend Yield	2.66%	2.16%	2.67%	9.39%
P/E Ratio	20.26	20.49	27.06	23.94
Price / Sales	2.26	300.33	514.89	90.87
Price / Cash	11.55	60.31	26.68	47.25
Price / Book	1.51	7.92	10.66	6.14
Net Income	$20.20M	$23.81M	$3.60B	$331.74M
7 Day Performance	-2.48%	-1.09%	-1.23%	-1.81%
1 Month Performance	-3.01%	2.56%	1.11%	-1.44%
1 Year Performance	-9.10%	42.16%	23.65%	16.33%

Kamada Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KMDA Kamada	4.8795 of 5 stars	$7.09 +0.6%	$12.00 +69.3%	-4.8%	$405.41M	$180.46M	20.26	360	News Coverage Gap Up
CMPS Compass Pathways	3.3499 of 5 stars	$12.52 -2.5%	$23.10 +84.6%	+171.4%	$1.69B	N/A	N/A	120	Gap Down High Trading Volume
SEPN Septerna	2.1661 of 5 stars	$36.57 +9.3%	$45.89 +25.5%	+156.7%	$1.65B	$45.95M	N/A	N/A
IMCR Immunocore	2.3344 of 5 stars	$32.27 +1.0%	$56.71 +75.7%	-6.2%	$1.64B	$400.02M	N/A	320	News Coverage Analyst Upgrade
AVBP ArriVent BioPharma	2.0615 of 5 stars	$34.69 +0.6%	$43.14 +24.4%	+28.0%	$1.62B	N/A	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KMDA) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kamada (KMDA) Competitors

KMDA vs. CMPS, SEPN, IMCR, AVBP, and MPLT

How does Kamada compare to Compass Pathways?

Summary

How does Kamada compare to Septerna?

Summary

How does Kamada compare to Immunocore?

Summary

How does Kamada compare to ArriVent BioPharma?

Summary

How does Kamada compare to Maplight Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KMDA vs. The Competition

Kamada Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kamada (KMDA) Competitors

KMDA vs. CMPS, SEPN, IMCR, AVBP, and MPLT

How does Kamada compare to Compass Pathways?

Which has more volatility and risk, CMPS or KMDA?

Is CMPS or KMDA more profitable?

Which has stronger earnings & valuation, CMPS or KMDA?

Does the media favor CMPS or KMDA?

Do analysts prefer CMPS or KMDA?

Do institutionals & insiders have more ownership in CMPS or KMDA?

Summary

How does Kamada compare to Septerna?

Do analysts recommend KMDA or SEPN?

Is KMDA or SEPN more profitable?

Do institutionals & insiders believe in KMDA or SEPN?

Which has stronger valuation and earnings, KMDA or SEPN?

Does the media refer more to KMDA or SEPN?

Which has more risk & volatility, KMDA or SEPN?

Summary

How does Kamada compare to Immunocore?

Which has preferable earnings & valuation, IMCR or KMDA?

Does the media favor IMCR or KMDA?

Do analysts recommend IMCR or KMDA?

Which has more volatility & risk, IMCR or KMDA?

Is IMCR or KMDA more profitable?

Do institutionals and insiders hold more shares of IMCR or KMDA?

Summary

How does Kamada compare to ArriVent BioPharma?

Do analysts rate AVBP or KMDA?

Which has stronger valuation & earnings, AVBP or KMDA?

Is AVBP or KMDA more profitable?

Do institutionals & insiders believe in AVBP or KMDA?

Which has more risk and volatility, AVBP or KMDA?

Does the media favor AVBP or KMDA?

Summary

How does Kamada compare to Maplight Therapeutics?

Does the media favor KMDA or MPLT?

Which has preferable earnings and valuation, KMDA or MPLT?

Do institutionals and insiders believe in KMDA or MPLT?

Is KMDA or MPLT more profitable?

Do analysts rate KMDA or MPLT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KMDA vs. The Competition

Kamada Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools